An interventional study of Panthea Core and Matched Placebo in Hypertension, sponsored by University of Minnesota. Not yet recruiting at 1 site in United States. Open to female participants aged 45 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by University of Minnesota · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Hypertension by University of Minnesota — 4 open to participants now, 5 under way, none of them phase 3. Hypertension · University of Minnesota.
Among the 23 studies in Hypertension by University of Minnesota, this one is the 10th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2027, is one of 8 with no phase, and was the 23rd registered.
6,125 studies on the registry are indexed under Hypertension; 910 are open to participants now.
Browse Hypertension studies →4 of the 23 studies in Hypertension by University of Minnesota are open now, in 1 country. Recruiting first, the newest first:
University of Minnesota · Sites in United States
Ages 18+ · Women only
University of Minnesota · Sites in United States
Ages 60+
University of Minnesota · Sites in United States
Ages 35–70 · Women only · Healthy volunteers
By country, each count listing its studies:
Of the 557 Hypertension studies recruiting now, 264 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 138 take healthy volunteers.
This study: 45 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 4 · Phase 3 2 · Phase 4 1
First in 1979; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 100 across 4,582 interventional studies indexed under Hypertension.
Median enrollment 79 across the 15 interventional studies, 81 across the 2 observational. Of the 18 that completed or were terminated, 4 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Minnesota is the lead sponsor of 1,218 studies on the registry; 198 are open to participants now.
Of its 136 completed or terminated interventional studies of FDA-regulated products, 95 (70%) have results posted.
1 of the studies in Hypertension by University of Minnesota that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04439370University of MinnesotaAutonomic Regulation of Blood Pressure in Premature and Early Menopausal Women | 2026-12-30 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies in Hypertension by University of Minnesota, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized, double-blind, placebo-controlled pilot study will investigate the effects of an Akkermansia muciniphila-based probiotic supplement, Panthea Core, on autonomic and vascular function in postmenopausal women with hypertension.
Up to 60 participants aged 45 to 65 years will be enrolled to obtain approximately 40 evaluable datasets. Participants will be randomly assigned to receive Panthea Core or a matched placebo capsule daily for 12 weeks.
The study will evaluate safety, tolerability, menopausal symptoms, and changes in autonomic and vascular physiology. The primary mechanistic outcome is muscle sympathetic nerve activity (MSNA), measured using microneurography. Secondary physiological outcomes include heart rate variability, baroreflex sensitivity, endothelial function assessed by flow-mediated dilation, and blood pressure.
Additional assessments will include sleep, menopausal symptoms, mood, cognitive function, circulating metabolic markers, and gut microbiome composition. Participants will complete baseline and post-intervention assessments, with additional safety monitoring throughout supplementation and approximately one month after the intervention.
Akkermansia muciniphila is a bacterium normally found in the human gastrointestinal tract that has been associated with metabolic and immune regulation. Previous research suggests that changes in Akkermansia muciniphila abundance may be related to blood pressure regulation, autonomic nervous system function, and vascular health. However, the effects of direct supplementation on human autonomic and endothelial physiology have not been adequately characterized.
This pilot study will evaluate the effects of a 12-week Akkermansia muciniphila-based probiotic supplement, Panthea Core, in postmenopausal women with hypertension. Hypertension is used as a physiological model of autonomic and vascular dysregulation, rather than as a treatment endpoint.
Participants will be randomized to Panthea Core or matched placebo in a double-blind, parallel-group design. The study plans to recruit up to 60 participants to obtain approximately 40 evaluable datasets.
Participants will complete three in-person study visits, including informed consent and two physiological assessment visits. During the baseline and post-intervention assessments, autonomic nervous system activity will be evaluated using microneurography to measure muscle sympathetic nerve activity, electrocardiography to assess heart rate variability, and physiological testing to assess baroreflex sensitivity.
Vascular endothelial function will be assessed using brachial artery flow-mediated dilation. Blood pressure and heart rate will also be measured.
Additional evaluations include laboratory safety measurements, metabolic and hormonal biomarkers, menopausal symptoms, sleep quality, mood, cognition, anthropometric measurements, dietary intake, and stool-based microbiome profiling.
Participants will take their assigned supplement or placebo daily for 12 weeks. Adverse events and gastrointestinal tolerability will be assessed through biweekly questionnaires and participant-initiated reporting. A follow-up contact approximately one month after the final testing visit will assess additional symptoms and adverse events.
The study is intended to generate preliminary mechanistic, safety, and tolerability data to inform the design of subsequent clinical research. As a pilot study, it is not powered to establish definitive treatment efficacy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to this group will receive one daily oral capsule of Panthea Core containing live Akkermansia muciniphila and additional dietary supplement ingredients for 12 weeks. Participants will undergo baseline and post-intervention assessments of autonomic and vascular function, safety, and related physiological outcomes.
Dietary Supplement: Panthea Core
Participants randomized to this group will receive a matched placebo capsule daily for 12 weeks. Participants will undergo the same baseline and post-intervention assessments as those assigned to Panthea Core.
Dietary Supplement: Matched Placebo
Panthea Core is an oral probiotic formulation containing live Akkermansia muciniphila (approximately 1 × 10\^8 active fluorescence units), pyridoxal-5'-phosphate (10 mg), spermidine trihydrochloride (1.2 mg), and 3,3'-diindolylmethane (100 mg). Participants will take the formulation once daily for 12 weeks. Study product will be distributed through the Investigational Drug Services Pharmacy.
Also known as: Akkermansia muciniphila-Based Probiotic, Panthea Core Supplementation
Participants will receive a matched oral placebo capsule administered once daily for 12 weeks. The placebo will be supplied by Panthea Inc. and dispensed through the Investigational Drug Services Pharmacy.
Also known as: Placebo for Panthea Core, Placebo
Change in Muscle Sympathetic Nerve Activity (MSNA)
Muscle sympathetic nerve activity will be measured using microneurography of the fibular nerve. MSNA burst frequency, expressed as bursts per minute, will be assessed at baseline and after 12 weeks of Panthea Core or placebo supplementation. Changes in MSNA will be compared between treatment groups.
Time frame: Baseline to 12 weeks
Incidence of Adverse Events
Adverse events and serious adverse events will be monitored throughout the intervention through biweekly REDCap questionnaires, participant-initiated reports, and post-intervention follow-up. The incidence and nature of adverse events will be summarized by treatment group to evaluate the safety and tolerability of Panthea Core.
Time frame: From initiation of supplementation through approximately 4 weeks after the 12-week intervention
Change in Comprehensive Metabolic Panel Laboratory Measures
Safety will be evaluated through changes in comprehensive metabolic panel laboratory measurements, including renal function, liver function, and electrolyte measurements. Laboratory results will be assessed at baseline and after 12 weeks of supplementation and summarized by treatment group.
Time frame: Baseline and 12 weeks
Supplement Adherence
Adherence to daily Panthea Core or placebo supplementation will be monitored throughout the intervention using participant-reported information collected through biweekly REDCap questionnaires. Adherence will be summarized descriptively, with a protocol target of at least 80%.
Time frame: Throughout the 12-week intervention
Study Retention
Study retention will be assessed as the proportion of enrolled participants who complete the planned intervention and post-intervention assessments. The protocol specifies a retention target of at least 75%.
Time frame: From enrollment through completion of the 12-week intervention
Change in Flow-Mediated Dilation (FMD)
Endothelial function will be assessed using brachial artery ultrasound flow-mediated dilation, expressed as percentage change in vessel diameter following temporary forearm occlusion.
Time frame: Baseline to 12 weeks
Change in Heart Rate Variability (HRV)
Cardiovagal modulation will be evaluated using time-domain and frequency-domain measures derived from electrocardiogram recordings.
Time frame: Baseline to 12 weeks
Change in Cardiovagal Baroreflex Sensitivity
Cardiovagal baroreflex sensitivity will be assessed using changes in ECG R-R intervals relative to changes in systolic blood pressure, expressed in ms/mmHg.
Time frame: Baseline to 12 weeks
Change in Sympathetic Baroreflex Sensitivity
Sympathetic baroreflex sensitivity will be evaluated using changes in MSNA relative to diastolic blood pressure, expressed in bursts/100 heartbeats/mmHg as described in the protocol.
Time frame: Baseline to 12 weeks
Change in Blood Pressure
Systolic and diastolic blood pressure will be measured at baseline and after the 12-week intervention to assess changes in blood pressure as a physiological parameter.
Time frame: Baseline to 12 weeks
Change in Menopause-Specific Quality of Life
Menopausal symptoms and quality of life will be assessed using the Menopause-Specific Quality of Life (MENQOL) questionnaire, including vasomotor, physical, psychosocial, and sexual domains.
Time frame: Baseline to 12 weeks
Change in Depressive Symptoms (PHQ-9)
Depressive symptoms will be evaluated using the nine-item Patient Health Questionnaire (PHQ-9).
Time frame: Baseline to 12 weeks
Change in Insomnia Severity (ISI)
Insomnia symptoms will be assessed using the seven-item Insomnia Severity Index.
Time frame: Baseline to 12 weeks
Change in Subjective Sleep Quality (PSQI)
(PSQI) Subjective sleep quality and disturbances will be assessed using the Pittsburgh Sleep Quality Index.
Time frame: Baseline to 12 weeks
Change in Objective Sleep Parameters
Sleep will be measured using WatchPAT ONE-M monitoring before baseline and post-intervention physiological testing.
Time frame: Baseline to 12 weeks
Change in Cognitive Function (MoCA)
Cognitive function will be evaluated using Montreal Cognitive Assessment scores before and after supplementation.
Time frame: Baseline to 12 weeks
Change in Gut Microbiome Composition
Fecal microbiome sequencing will be used to evaluate changes in microbial composition and the abundance of Akkermansia muciniphila after supplementation.
Time frame: Baseline to 12 weeks
Start is estimated for Feb 2027; primary completion for Jan 2030, 35 months later.
Of 1,406 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 35 months is above that.
Counting every sponsor, half of 1,501 studies reached it within 23 months; a quarter within 10 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.